Drug Trial Radar · NCT01954316
A Study of CFI-400945 Fumarate in Patients With Advanced Cancer
Last checked: Nov 20, 2026Latest source record: Jan 17, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
46
Actual
Start
Mar 2014
Primary completion
Jul 2021
Study completion Jul 22, 2021
Sponsor
- Lead sponsor
- University Health Network, TorontoAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- The Princess Margaret Cancer Foundation; California Institute for Regenerative Medicine (CIRM)
- First posted
- Oct 1, 2013
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase 1 study to test different doses of a new investigational drug called CFI-400945 to see which dose is safer in people. This study will also look at the safety of CFI-400945 and to study its effects on patients with advanced cancers. This drug has been tested in animals but not yet in people. CFI-400945 is an oral (taken by mouth) drug that works by blocking polo-like kinase 4 (PLK4) from working. PLK4 is a protein that is important in regulating cell growth and division and cell death. Many tumors are shown to make too much PLK4. When there is too much PLK4 produced, it is believed to lead to uncontrolled cancer cell growth and division. Therefore, by blocking this protein from working, it is believed to stop tumors growing or shrink them.
Conditions
- Advanced Cancer
Interventions
CFI-400945Drug
Polo-like kinase 4 (PLK4) inhibitor
Primary outcomes
What the sponsor says the trial is designed to measure.
- Highest dose level that does not lead to unacceptable toxicity in two or more patients in a dosing group over a range of doses and schedulesTime frame: From first dose of study drug until the date of unacceptable toxicity, throughout the study completion, up to 2 years
Locations
2 sites in 2 countries. Site status is shown where the registry gives one.
UCLA Medical Center
Santa Monica, California
Princess Margaret Cancer Centre
Toronto, Ontario, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.